Spinal zaps may soothe chemo nerve pain
NCT ID NCT05411523
First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times
Summary
This study tests whether spinal cord stimulation (SCS) can reduce pain and improve quality of life in people with chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes numbness, tingling, and pain, often in the hands and feet. Researchers will follow 20 adults who have had CIPN for at least six months and have not found relief from standard pain medications. Participants will receive SCS therapy and be monitored for up to 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- spinal cord stimulation
- What this could lead to
- If it works, this could offer a new way to manage chronic nerve pain from chemotherapy without relying on medications.
- What could go wrong
- This is a small, early observational study with only 20 participants, so results may not apply to everyone. The procedure carries risks like infection or lead movement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients diagnosed with CIPN.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients greater than or equal to 18 years of age who have been clinically diagnosed with CIPN for greater than six months after stopping chemotherapy * Average pain intensity \>= 5 on 11-point numeric rating scale (NRS) in the lower extremities at enrollment * Failed conventional medication management with at least two neuropathic pain medications * Have electrophysiological evidence of length-dependent peripheral neuropathy * Underwent a 10-kHz spinal cord stimulator trial for a primary indication of CIPN and reported a successful trial of at least 75% reduction in pain intensity * Have stable neurological status * Be on a stable analgesic regimen * Be an appropriate candidate for surgical procedures required in this study * Be able to read and understand English-written questionnaires and sign an informed consent form in English * Be willing and capable of giving informed consent * Be willing and able to complete study-related requirements, procedures, and visits Exclusion Criteria: * Patient refusal to be included in study * Presence of lower limb mononeuropathy * History of lower limb amputation or ulceration * Presence of another painful condition that is unrelated to CIPN and that is not intended to be treated in this study * Body mass index (BMI) \>= 40 * Omeprazole (OME) \> 120 mg * Progressive neurological disease (multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, complex regional pain syndrome, acute herniating disc, severe spinal stenosis) * Certain comorbidities: coagulation/bleeding disorders, diminished capacity from cardiac/pulmonary disease * Obtaining another interventional procedure unrelated to SCS to treat limb pain * Have ongoing metastatic malignant neoplasm or untreated local malignant neoplasm. Included patients must be deemed as in remission per discretion of treating oncologist * Have a life expectancy of less than one year * Have untreated addiction or dependency to medications, alcohol, or illicit drugs * Have active, disruptive, and/or unstable psychological or psychiatric disorder
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can TENS, compression, or cold therapy stop chemo nerve pain?
- Can a phone app help childhood cancer survivors keep track of their health?
- Can an antidepressant calm Chemotherapy's nerve pain?
- Retraining the senses to fight chemotherapy nerve damage
- Can the way we word cancer research invitations boost participation?